Immuneering Corporation
Industry
- Biotechnology
- Drug Discovery Technologies
- Bioinformatics
- Genomics-Proteomics
- Pharmacogenetics-Pharmacogenomics
- Drug Discovery Technologies
- Pharmaceuticals
Latest on Immuneering Corporation
Immuneering Corporation is planning a global pivotal trial in 2026 for atebimetinib in first-line pancreatic cancer after posting successful results of a Phase IIa study of the drug. Immuneering is ai
“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning
Biotechnology stocks in the US are still trading lower year-to-date, but valuations have risen significantly in April, suggesting that perhaps the winter chill hovering over the industry is beginning
With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue